Thomas O Carpenter (T O Carpenter, Thomas Carpenter)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 17

Top Topics

Monoclonal Antibody

Replacement Therapy

Mitochondrial Dna

Top Venues

The Journal of clinical endocrinology and metabolism

JCEM case reports

This page only lists publications with an associated author ORCID identifier.

Publications

Bracha Goldsweig, R Sena Turk Yilmaz, Apoorva Ravindranath Waikar, Catherine Brownstein, Thomas O Carpenter
Familial Hypocalciuric hypercalcemia in an infant: diagnosis and management quandaries. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research (2024)
Ernst J Reichenberger, Kevin O'Brien, Ayano Hatori, Thomas O Carpenter, Koen van de Wetering, Lisa Flaman, Jennifer Howe, Daniel Ortiz, Yves Sabbagh, I-Ping Chen
ENPP1 enzyme replacement therapy improves ectopic calcification but does not rescue skeletal phenotype in a mouse model for craniometaphyseal dysplasia. JBMR plus 8 (9) (2024)
Suzanne M Jan de Beur, Kathryn M Dahir, Erik A Imel, María Belén Zanchetta, Angela Williams, Zhiyi Li, Neil Webb, Victoria Crowe, Ben Johnson, Thomas O Carpenter
Healthcare resource use associated with tumor-induced osteomalacia: a literature review. The Journal of clinical endocrinology and metabolism (2024)
Ernst J Reichenberger, Kevin O'Brien, Ayano Hatori, Thomas O Carpenter, Koen van de Wetering, Lisa Flaman, Jennifer Howe, Daniel Ortiz, Yves Sabbagh, I-Ping Chen
ENPP1 enzyme replacement therapy improves ectopic calcification but does not rescue skeletal phenotype in a mouse model for craniometaphyseal dysplasia. JBMR plus 8 (9) (2024)
Ernst J Reichenberger, Kevin O'Brien, Ayano Hatori, Thomas O Carpenter, Koen van de Wetering, Lisa Flaman, Jennifer Howe, Daniel Ortiz, Yves Sabbagh, I-Ping Chen
ENPP1 enzyme replacement therapy improves ectopic calcification but does not rescue skeletal phenotype in a mouse model for craniometaphyseal dysplasia. JBMR plus 8 (9) (2024)
Miles D Thompson, Xueying Li, Michele Spencer-Manzon, Danielle M Andrade, Yoshiko Murakami, Taroh Kinoshita, Thomas O Carpenter
Excluding Digenic Inheritance of PGAP2 and PGAP3 Variants in Mabry Syndrome (OMIM 239300) Patient: Phenotypic Spectrum Associated with PGAP2 Gene Variants in Hyperphosphatasia with Mental Retardation Syndrome-3 (HPMRS3). Genes 14 (2) (2023)
Miles D Thompson, Xueying Li, Michele Spencer-Manzon, Danielle M Andrade, Yoshiko Murakami, Taroh Kinoshita, Thomas O Carpenter
Excluding Digenic Inheritance of PGAP2 and PGAP3 Variants in Mabry Syndrome (OMIM 239300) Patient: Phenotypic Spectrum Associated with PGAP2 Gene Variants in Hyperphosphatasia with Mental Retardation Syndrome-3 (HPMRS3). Genes 14 (2) (2023)
Miles D Thompson, Xueying Li, Michele Spencer-Manzon, Danielle M Andrade, Yoshiko Murakami, Taroh Kinoshita, Thomas O Carpenter
Excluding Digenic Inheritance of PGAP2 and PGAP3 Variants in Mabry Syndrome (OMIM 239300) Patient: Phenotypic Spectrum Associated with PGAP2 Gene Variants in Hyperphosphatasia with Mental Retardation Syndrome-3 (HPMRS3). Genes 14 (2) (2023)
Miles D Thompson, Xueying Li, Michele Spencer-Manzon, Danielle M Andrade, Yoshiko Murakami, Taroh Kinoshita, Thomas O Carpenter
Excluding Digenic Inheritance of PGAP2 and PGAP3 Variants in Mabry Syndrome (OMIM 239300) Patient: Phenotypic Spectrum Associated with PGAP2 Gene Variants in Hyperphosphatasia with Mental Retardation Syndrome-3 (HPMRS3). Genes 14 (2) (2023)
Christine A Simpson, Anna Maria Santoro, Thomas O Carpenter, Yanhong Deng, Stephen Parziale, Karl L Insogna
Circulating Levels of Leptin and Lipocalin-2 in Patients With X-Linked Hypophosphatemia. Journal of the Endocrine Society 7 (11) (2023)
Michelle Kayser, Preti Jain, Allen Bale, Thomas O Carpenter
A De Novo Deleterious PHEX Variant Without Clinical Features of X-Linked Hypophosphatemia. JCEM case reports 1 (5) (2023)
Miles D Thompson, Xueying Li, Michele Spencer-Manzon, Danielle M Andrade, Yoshiko Murakami, Taroh Kinoshita, Thomas O Carpenter
Excluding Digenic Inheritance of PGAP2 and PGAP3 Variants in Mabry Syndrome (OMIM 239300) Patient: Phenotypic Spectrum Associated with PGAP2 Gene Variants in Hyperphosphatasia with Mental Retardation Syndrome-3 (HPMRS3). Genes 14 (2) (2023)
Thomas J Weber, Erik Allen Imel, Thomas O Carpenter, Munro Peacock, Anthony A Portale, Joel Hetzer, J Lawrence Merritt, Karl Insogna
Long-Term Burosumab Administration is Safe and Effective in Adults With X-Linked Hypophosphatemia (XLH). The Journal of clinical endocrinology and metabolism (2022)
Maria Luisa Brandi, Suzanne M Jan de Beur, Karine Briot, Thomas O Carpenter, Hae Il Cheong, Martine Cohen Solal, Rachel Katherine Crowley, Richard Eastell, Yasuo Imanishi, Erik Allen Imel, Steven W Ing, Karl L Insogna, Nobuaki Ito, Muhammad Kassim Javaid, Peter Kamenickỷ, Richard Keen, Takuo Kubota, Robin H Lachmann, Farzana Perwad, Pisit Pitukcheewanont, Anthony A Portale, Stuart H Ralston, Hiroyuki Tanaka, Thomas J Weber, Han Wook Yoo, Wei Sun, Angela Williams, Annabel Nixon, Yasuhiro Takeuchi
Efficacy of Burosumab in Adults with X-linked Hypophosphatemia (XLH): A Post Hoc Subgroup Analysis of a Randomized Double-Blind Placebo-Controlled Phase 3 Study. Calcified tissue international 111 (4) (2022)
I N Choksi, Allison J Cox, Cemre Robinson, A Bale, Thomas O Carpenter
Novel homozygous variant in BMP1 associated with a rare osteogenesis imperfecta phenotype. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 32 (6) (2021)
Agnès Linglart, Erik Allen Imel, Michael P Whyte, Anthony A Portale, Wolfgang Högler, Annemieke M Boot, Raja Padidela, William Van't Hoff, Gary S Gottesman, Angel Chen, Alison Skrinar, Mary Scott Roberts, Thomas O Carpenter
Sustained efficacy and safety of burosumab, a monoclonal antibody to FGF23, in children with X-linked hypophosphatemia. The Journal of clinical endocrinology and metabolism (2021)
Abigail S Eswarakumar, Nina S Ma, Leanne M Ward, Philippe Backeljauw, Halley Wasserman, David R Weber, Linda A DiMeglio, Erik A Imel, Julie Gagne, Declan Cody, Paul Zimakas, Lisa Swartz Topor, Sungeeta Agrawal, Andrew Calabria, Peter Tebben, Ruth S Faircloth, Rebecca Gordon, Linda Casey, Thomas O Carpenter
Long-Term Follow-up of Hypophosphatemic Bone Disease Associated With Elemental Formula Use: Sustained Correction of Bone Disease After Formula Change or Phosphate Supplementation. Clinical pediatrics 59 (12) (2020)